Chinese Journal of Tissue Engineering Research ›› 2010, Vol. 14 ›› Issue (53): 9897-9901.doi: 10.3969/j.issn.1673-8225.2010.53.004

Previous Articles     Next Articles

Fluctuation of soluble intercellular adhesion molecule-1 prior to and after lung transplantation

Zhang Di1, Yu Jing-feng2, Xiao Hua-long2   

  1. 1 Department of Internal Medicine, 2 Department of Laboratory Medicine, Wuxi People’s Hospital, Nanjing Medical University, Wuxi  214023, Jiangsu Province, China
  • Online:2010-12-31 Published:2010-12-31
  • Contact: Xiao Hua-long, Chief technician, Associate professor, Master’s supervisor, Department of Laboratory Medicine, Wuxi People’s Hospital, Nanjing Medical University, Wuxi 214023, Jiangsu Province, China
  • About author:Zhang Di, Chief physician, Department of Internal Medicine, Wuxi People’s Hospital, Nanjing Medical University, Wuxi 214023, Jiangsu Province, China gxh913@163.com
  • Supported by:

    the Open Subjects for Key Laboratory of Nuclear Medicine, Ministry of Public Health, No. WK005-021*

PDF

414

Abstract:

BACKGROUND: The soluble intercellular adhesion molecule-1 (sICAM-1) assay is based on biotin-streptavidin (BSA) system and has been widely used due to high sensitivity. 
OBJECTIVE: To establish sICAM-1 BAS time resolution fluoroimmunoassay method (sICAM-1 BAS-TRFIA) and to explore the sICAM-1 fluctuation and clinical significance prior to and after lung transplantation.
METHODS: Two matching monoclonal antibodies served as capture immune body and the examination immune body, respectively. The europium-labeled streptavidin (SA-Eu 3+ ) served as tracer and combined with biotinylated immune body to establish the sICAM-1 BSA-TRFIA method. This method was used to detect sICAM-1 levels in 30 healthy adults and 26 recipients prior to and after lung transplantation. The clinical significance of sICAM-1 BSA-TRFIA method was evaluated.
RESULTS AND CONCLUSION: The determine results of 30 healthy adults were (348.63±69.12) µg/L. There was no significant difference in sICAM-1 between control and prior to transplantation group. After transplantation, there was obviously difference  (P < 0.05). The sICAM-1 increased when acute rejection occurs but decreased after concurrent infection, but the differences had no significant. The findings demonstrated that, sICAM-1 BSA-TRFIA method is a novel non-radioactive labeled immunoassay with high sensitivity and wide scope. Monitoring of serum sICAM-1 is helpful to auxiliary diagnosis acute rejection following lung transplantation.

CLC Number: